Trials / Unknown
UnknownNCT00033072
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.
Detailed description
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg \& 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selegiline |
Timeline
- Start date
- 2001-09-01
- Completion
- 2002-10-01
- First posted
- 2002-04-08
- Last updated
- 2017-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00033072. Inclusion in this directory is not an endorsement.